{"id":"NCT03256695","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","briefTitle":"Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD)","officialTitle":"A 12-Week, Open-Label Study to Evaluate the Relationship Between Use of Albuterol eMDPI, an Inhaled Short-Acting Beta Agonist \"Rescue\" Agent With an eModule, and Exacerbations in Patients (40 Years of Age or Older) With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-09-28","primaryCompletion":"2018-04-17","completion":"2018-04-17","firstPosted":"2017-08-22","resultsPosted":"2019-08-06","lastUpdate":"2021-11-09"},"enrollment":405,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Obstructive Pulmonary Disease"],"interventions":[{"type":"DRUG","name":"Albuterol sulfate (ABS)","otherNames":[]}],"arms":[{"label":"ABS eMDPI","type":"EXPERIMENTAL"}],"summary":"This is a Phase 3B, 12-week, multicenter, open-label study to evaluate the relationship between as-needed usage of albuterol eMDPI and Clinical Exacerbation-Chronic Obstructive Pulmonary Disease (CE-COPD) in adult participants at least 40 years of age with exacerbation-prone COPD.","primaryOutcome":{"measure":"Clinical Exacerbation of COPD (CE-COPD) Rate: Percentage of Participants Who Experienced at Least 1 Moderate or Severe CE-COPD","timeFrame":"Baseline (Day 1) to Week 12","effectByArm":[{"arm":"ABS eMDPI","deltaMin":28,"sd":null}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":6},"locations":{"siteCount":40,"countries":["United States"]},"refs":{"pmids":["40355297"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":44,"n":405},"commonTop":["Chronic obstructive pulmonary disease"]}}